Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Supplementary Materials of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (9288)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
Oct 26, 2020 (publication date) through Feb 14, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Cardiology
ISSN
1949-8462
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Ullah W, Mukhtar M, Al-Mukhtar A, Saeed R, Boigon M, Haas D, Rame E. Safety and efficacy of soluble guanylate cyclase stimulators in patients with heart failure: A systematic review and meta-analysis. World J Cardiol 2020; 12(10): 501-512 [PMID: 33173569 DOI: 10.4330/wjc.v12.i10.501] |
|---|---|
| URL: | https://www.wjgnet.com/1949-8462/full/v12/i10/501.htm |
| Number | Citing Articles |
| 1 |
Ravi A. Thakker, Ayman Elbadawi, Aiham Albaeni, Christopher Perez, Syed Mustajab Hasan, Jose Iturrizaga Murrieta, Ahmed Almustafa, Alexander Duarte, Rafic F. Berbarie, Khaled F. Chatila, Wissam Khalife. Outcomes With sGC Therapy in Patients With HFpEF: A Meta-Analysis of Prior Trials. Current Problems in Cardiology 2022; 47(9): 100924 doi: 10.1016/j.cpcardiol.2021.100924
|
| 2 |
Xiao-Yan Jia, Yong-Ming Liu, Yong-Fei Wang, Jin-Yang An, Ke-Ling Peng, Hua Wang. Bibliometric study of soluble guanylate cyclase stimulators in cardiovascular research based on web of science from 1992 to 2021. Frontiers in Pharmacology 2022; 13 doi: 10.3389/fphar.2022.963255
|
| 3 |
Alfredo Parra-Lucares, Esteban Romero-Hernández, Eduardo Villa, Sebastián Weitz-Muñoz, Geovana Vizcarra, Martín Reyes, Diego Vergara, Sergio Bustamante, Marcelo Llancaqueo, Luis Toro. New Opportunities in Heart Failure with Preserved Ejection Fraction: From Bench to Bedside… and Back. Biomedicines 2022; 11(1): 70 doi: 10.3390/biomedicines11010070
|
| 4 |
Yang Zhao, Bin Zang, Qian Wang. Soluble guanylate cyclase (sGC) stimulators in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Shock 2023; doi: 10.1097/SHK.0000000000002277
|
| 5 |
Steven G. Chrysant. A novel approach for the treatment of hypertension with the soluble guanylate cyclase stimulating drug. Expert Opinion on Drug Safety 2021; 20(6): 635 doi: 10.1080/14740338.2021.1906221
|
| 6 |
Nima Moghaddam, Navraj Malhi, Mustafa Toma. Impact of oral soluble guanylate cyclase stimulators in heart failure: A systematic review and Meta-analysis of randomized controlled trials. American Heart Journal 2021; 241: 74 doi: 10.1016/j.ahj.2021.07.003
|
| 7 |
Andrew J. S. Coats, Heli Tolppanen. Drug Treatment of Heart Failure with Reduced Ejection Fraction: Defining the Role of Vericiguat. Drugs 2021; 81(14): 1599 doi: 10.1007/s40265-021-01586-y
|
| 8 |
Mehmet Emin Arayici, Hakan Gunes, Hulya Ellidokuz, Mehmet Birhan Yilmaz. The efficacy and safety of soluble guanylate cyclase modulation in patients with heart failure: a comprehensive meta-analysis of randomized controlled trials. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-57695-7
|